vs

Side-by-side financial comparison of Ovid Therapeutics Inc. (OVID) and ZenaTech, Inc. (ZENA). Click either name above to swap in a different company.

ZenaTech, Inc. is the larger business by last-quarter revenue ($941.9K vs $718.0K, roughly 1.3× Ovid Therapeutics Inc.).

ZenaTech, Inc. is a technology firm specializing in AI-integrated drone solutions and enterprise SaaS platforms for industrial and public sector clients. Its core offerings include purpose-built drone hardware, fleet management tools, and actionable data analytics, serving key markets such as public safety, infrastructure inspection, agriculture, and logistics across North America.

OVID vs ZENA — Head-to-Head

Bigger by revenue
ZENA
ZENA
1.3× larger
ZENA
$941.9K
$718.0K
OVID

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
OVID
OVID
ZENA
ZENA
Revenue
$718.0K
$941.9K
Net Profit
Gross Margin
Operating Margin
Net Margin
Revenue YoY
844.7%
Net Profit YoY
204.4%
EPS (diluted)
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OVID
OVID
ZENA
ZENA
Q4 25
$718.0K
Q3 25
$132.0K
$941.9K
Q2 25
$6.3M
$702.6K
Q1 25
$130.0K
$431.7K
Q4 24
$76.0K
Q3 24
$173.0K
$820.1K
Q2 24
$169.0K
Q1 24
$148.0K
Net Profit
OVID
OVID
ZENA
ZENA
Q4 25
Q3 25
$-12.2M
Q2 25
$-4.7M
Q1 25
$-10.2M
Q4 24
Q3 24
$-14.0M
Q2 24
$8.5M
Q1 24
$-11.7M
Operating Margin
OVID
OVID
ZENA
ZENA
Q4 25
Q3 25
-9487.1%
Q2 25
-80.9%
Q1 25
-9653.8%
Q4 24
Q3 24
-7645.1%
Q2 24
-12140.2%
Q1 24
-11768.2%
Net Margin
OVID
OVID
ZENA
ZENA
Q4 25
Q3 25
-9210.6%
Q2 25
-74.7%
Q1 25
-7873.1%
Q4 24
Q3 24
-8096.0%
Q2 24
5042.0%
Q1 24
-7901.4%
EPS (diluted)
OVID
OVID
ZENA
ZENA
Q4 25
Q3 25
$-0.49
Q2 25
$-0.01
Q1 25
Q4 24
Q3 24
$-0.20
Q2 24
$0.12
Q1 24
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OVID
OVID
ZENA
ZENA
Cash + ST InvestmentsLiquidity on hand
$13.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$130.7M
Total Assets
$150.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OVID
OVID
ZENA
ZENA
Q4 25
$13.2M
Q3 25
$20.6M
Q2 25
$28.4M
Q1 25
$21.1M
Q4 24
$26.3M
Q3 24
$15.0M
Q2 24
$29.7M
Q1 24
$30.8M
Stockholders' Equity
OVID
OVID
ZENA
ZENA
Q4 25
$130.7M
Q3 25
$44.7M
Q2 25
$55.8M
Q1 25
$59.3M
Q4 24
$68.2M
Q3 24
$76.3M
Q2 24
$88.9M
Q1 24
$78.3M
Total Assets
OVID
OVID
ZENA
ZENA
Q4 25
$150.9M
Q3 25
$63.8M
Q2 25
$77.4M
Q1 25
$81.7M
Q4 24
$92.2M
Q3 24
$102.7M
Q2 24
$118.1M
Q1 24
$131.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OVID
OVID
ZENA
ZENA
Operating Cash FlowLast quarter
$-38.3M
$-3.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OVID
OVID
ZENA
ZENA
Q4 25
$-38.3M
Q3 25
$-12.9M
$-3.1M
Q2 25
$-4.8M
$-941.0K
Q1 25
$-10.3M
$-396.2K
Q4 24
$-56.0M
Q3 24
$-15.0M
$-3.1M
Q2 24
$-14.3M
Q1 24
$-16.7M
Free Cash Flow
OVID
OVID
ZENA
ZENA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$-56.0M
Q3 24
$-15.0M
Q2 24
$-14.3M
Q1 24
$-16.7M
FCF Margin
OVID
OVID
ZENA
ZENA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-73719.7%
Q3 24
-8676.9%
Q2 24
-8455.0%
Q1 24
-11287.2%
Capex Intensity
OVID
OVID
ZENA
ZENA
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
93.4%
Q3 24
2.3%
Q2 24
20.1%
Q1 24
12.8%
Cash Conversion
OVID
OVID
ZENA
ZENA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-1.67×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons